Year Founded
1999
Ownership
Public
Employees
~50
Stage
Commercial
Modalities
Small molecule

Akros Pharma General Information

Tirbanibulin 1% ointment approved for actinic keratosis treatment with high efficacy in Phase 3 trials (44-54% complete clearance) and favorable safety profile. Short 5-day treatment regimen with mild local skin reactions that resolve quickly.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Princeton, New Jersey
United States

Drug Pipeline

tirbanibulin
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Akros Pharma's pipeline data

Book a demo

Key Partnerships

JT Pharmaceuticals, United Health Care, Medidata

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Akros Pharma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Akros Pharma's complete valuation and funding history, request access »

Akros Pharma Investors

Parent company Japan Tobacco Inc.; no external investors listed.
Investor Type: Venture Capital
Holding: Minority